Alprolix

Product Specs	Description
Manufacturer Name	Sanofi
Description	ALPROLIX, Coagulation Factor IX (Recombinant), Fc Fusion Protein, is a recombinant DNA derived coagulation Factor IX concentrate indicated in adults and children with hemophilia B (congenital Factor IX deficiency). ALPROLIX is not indicated for induction of immune tolerance in patients with hemophilia B
Indications for Adults:
Control and Prevention of Bleeding Episodes	Yes
Perioperative Management	Yes
Routine Prophylaxis to Prevent or Reduce the Frequency of Bleeding Episodes	Yes
Indications for Children:
Control and Prevention of Bleeding Episodes	Yes
Perioperative Management	Yes
Routine Prophylaxis to Prevent or Reduce the Frequency of Bleeding Episodes	Yes
Contraindications Nutrient in Cell Culture	Do not use in individuals who have a known history of hypersensitivity reactions, including anaphylaxis, to the product or its excipients.
Viral Safety Process	Detergent treatment, 15 nm filtration
Product Half-Life	Terminal* Half-Life: Adults: 86 to 97 hours Adolescents 12-17 years: 80 hours
Product Recovery Percentage Mean incremental recovery IR (IU/dL per IU/kg)	Adults: 1.02 (59) Adolescents 12-17 years: 0.87 (44)
Manufacturing Method	ALPROLIX is a recombinant factor IX
Storage Requirements/Shelf Life	Store in the original package in order to protect it from light. Store at 2°C to 8°C (36°F to 46°F). Do not freeze. Can be stored at room temperature, not to exceed 30°C (86°F), for a single period of up to 6 months within the expiration date printed on the label. Do not place the product back into refrigeration after warming to room temperature. Do not use product or diluent after the expiration date printed on the label. Reconstituted product may be stored at room temperature, not to exceed 30°C (86°F) for no longer than 3 hours. Protect from direct sunlight.
Nominal Vial Size & Diluent Volume	250, 500, 1000, 2000, 3000, or 4000 IU/5 mL

*Note: Terminal half-life is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose. (Toutain PL, et al. J Vet Pharmacoll Ther. 2004.)